At the 2022 AACR Annual Meeting, Repare Therapeutics presented data from the ongoing TRESR study, which showed that treatment with camonsertib monotherapy achieved durable clinical benefits across tumor types and genomic alterations. In fact, the overall clinical benefit rate (CBR) for all patients ...